NR First to Receive Pharmacopeial Quality Benchmark
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 09 2026
0mins
Should l Buy NAGE?
Source: Newsfilter
- Industry Leadership: Niagen Bioscience's Nicotinamide Riboside Chloride (NRCl) becomes the first ingredient to receive a United States Pharmacopeia (USP) standard, reinforcing the company's leadership in NAD+ science and ingredient quality, and is expected to drive standardization across the NAD+ supplement industry.
- Scientific Rigor: The monograph is based on Niagen's scientific data and analytical methods, establishing quality requirements for NRCl, including purity, potency, and testing methods, ensuring consumers receive high-quality supplements and enhancing market trust.
- Long-term Collaboration: Niagen Bioscience collaborated with USP for six years, contributing analytical methods and specifications to successfully establish the NRCl standard, which is expected to be codified and enforced in 2026, further solidifying the company's market position.
- Market Impact: The pharmacopeial standard for NRCl not only enhances Niagen's brand image but may also drive consumer demand for high-quality NAD+ supplements, promoting future sales growth and market share expansion for the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NAGE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NAGE
Wall Street analysts forecast NAGE stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.840
Low
12.00
Averages
16.33
High
23.00
Current: 4.840
Low
12.00
Averages
16.33
High
23.00
About NAGE
Niagen Bioscience, Inc. is a global bioscience company dedicated to promoting healthy aging. Its segments include Consumer Products, Ingredients segment, Analytical Reference Standards and Services and Pharmaceuticals. The Consumer Products segment provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors. The ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and outsourcing facilities. The Analytical Reference Standards and Services segment offer the supply of phytochemical reference standards and other research and development services. The Pharmaceutical segment focuses on the pharmaceutical development of its nicotinamide adenine dinucleotide (NAD) precursor portfolio for potential therapeutic applications in rare diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NR First to Receive Pharmacopeial Quality Benchmark
- Industry Leadership: Niagen Bioscience's Nicotinamide Riboside Chloride (NRCl) becomes the first ingredient to receive a United States Pharmacopeia (USP) standard, reinforcing the company's leadership in NAD+ science and ingredient quality, and is expected to drive standardization across the NAD+ supplement industry.
- Scientific Rigor: The monograph is based on Niagen's scientific data and analytical methods, establishing quality requirements for NRCl, including purity, potency, and testing methods, ensuring consumers receive high-quality supplements and enhancing market trust.
- Long-term Collaboration: Niagen Bioscience collaborated with USP for six years, contributing analytical methods and specifications to successfully establish the NRCl standard, which is expected to be codified and enforced in 2026, further solidifying the company's market position.
- Market Impact: The pharmacopeial standard for NRCl not only enhances Niagen's brand image but may also drive consumer demand for high-quality NAD+ supplements, promoting future sales growth and market share expansion for the company.
See More
Niagen IV Launches at High-End Cruise Medi-Spa Clinics
- New Partnership: Niagen Bioscience has partnered with OneSpaWorld to offer pharmaceutical-grade Niagen IV at over 80 high-end cruise Medi-Spa clinics, marking its first entry into the cruise market, which is expected to significantly enhance brand visibility and market share.
- Market Expansion: This collaboration provides Niagen IV with a new access point outside the U.S., catering to high-end consumers seeking health and longevity experiences while on vacation, thereby driving sales growth and brand influence.
- Product Advantages: The next-generation Niagen IV formulation offers 75% shorter infusion times and a faster rise in NAD+ blood levels compared to traditional NAD+ IV, which is anticipated to improve patient experience and attract more customers.
- Strategic Implications: By partnering with OneSpaWorld, Niagen Bioscience not only expands its clinical channels but also strengthens its competitive position in the global health and longevity market, further solidifying its industry leadership.
See More
Niagen Bioscience Increases Share Repurchase Program to $20 Million
- Repurchase Program Expansion: Niagen Bioscience has increased its share repurchase program authorization from $10 million to $20 million, reflecting the company's confidence in its stock value, which is expected to enhance investor sentiment and potentially boost stock performance.
- Repurchase Progress: As of March 17, 2026, the company has repurchased approximately $2.6 million of its common stock under the program, indicating proactive measures to protect shareholder interests amid market fluctuations and reinforcing confidence in its financial health.
- Performance Beats Expectations: Niagen Bioscience reported a GAAP EPS of $0.05, beating estimates by $0.03, and revenue of $33.84 million, exceeding expectations by $2.14 million, demonstrating the company's ability to maintain strong growth in a competitive supplement market.
- Future Growth Targets: The company aims for a revenue growth of 10-15% by 2026 while expanding its injectable product line, indicating strategic decisions focused on product diversification and market share enhancement to further solidify its market position.
See More
Niagen Bioscience Expands Share Repurchase Program to $20 Million
- Program Expansion: Niagen Bioscience has increased its share repurchase program authorization from $10 million to $20 million, reflecting the company's strong confidence in its long-term strategy and value, which is expected to enhance market recognition of its stock.
- Repurchase Progress: As of March 17, 2026, the company has repurchased approximately $2.6 million of its common stock, indicating proactive measures taken to capitalize on market undervaluation, thereby strengthening investor trust.
- Flexibility in Repurchases: The repurchase program is authorized through October 31, 2027, allowing the company to execute buybacks flexibly based on market conditions, potentially through open market transactions or privately negotiated deals, enhancing capital management flexibility.
- Strategic Implications: CEO Rob Fried emphasized that the repurchase program not only reflects confidence in the company's fundamentals but also aims to leverage the disconnect in market valuation of NAGE, thereby creating long-term value for shareholders and further solidifying the company's market position.
See More
Niagen Bioscience to Participate in ROTH Conference
- Management Participation: Niagen Bioscience's senior management will attend the 2026 ROTH Conference, showcasing the company's leadership in healthy aging and likely attracting investor interest while enhancing brand visibility.
- CEO Panel Discussion: CEO Rob Fried will participate in the Technologies Advancing Healthy Aging panel on March 23, with the livestream broadening audience access to the company's innovations in NAD+ science, potentially fostering future investment opportunities.
- One-on-One Investor Meetings: Rob Fried and CFO Ozan Pamir will engage in face-to-face meetings with institutional investors, strengthening relationships with potential investors and driving company financing and market expansion.
- Industry Networking Platform: The conference will gather executives from numerous private and public companies, providing small group discussions and analyst-selected fireside chats, facilitating knowledge sharing and collaboration within the industry, thereby enhancing Niagen's influence in the sector.
See More
Niagen Bioscience Surpasses 300 Research Agreements, Strengthening NAD+ Research
- Research Agreement Milestone: Niagen Bioscience's external research program has surpassed 300 material transfer agreements (MTAs), marking its leading position in global NAD+ research support and is expected to further enhance the company's influence in the healthy aging sector.
- Clinical Research Outcomes: The program has contributed to the publication of 45 clinical studies, demonstrating the effectiveness and safety of Niagen as an NAD+ booster, thereby enhancing its credibility and competitive edge in the scientific community.
- International Collaboration Expansion: With agreements established with over 200 institutions across 34 countries, the growing global interest in NAD+ biology positions Niagen as a trusted NAD+ booster for researchers, promoting independence and rigor in scientific research.
- Future Research Directions: Niagen Bioscience plans to expand its research into areas such as topical applications and pharmaceutical-grade Niagen intravenous injections, aiming to meet the increasing interest in NAD+ biology and further explore its potential in health and aging.
See More
NR First to Receive Pharmacopeial Quality Benchmark
- Industry Leadership: Niagen Bioscience's Nicotinamide Riboside Chloride (NRCl) becomes the first ingredient to receive a United States Pharmacopeia (USP) standard, reinforcing the company's leadership in NAD+ science and ingredient quality, and is expected to drive standardization across the NAD+ supplement industry.
- Scientific Rigor: The monograph is based on Niagen's scientific data and analytical methods, establishing quality requirements for NRCl, including purity, potency, and testing methods, ensuring consumers receive high-quality supplements and enhancing market trust.
- Long-term Collaboration: Niagen Bioscience collaborated with USP for six years, contributing analytical methods and specifications to successfully establish the NRCl standard, which is expected to be codified and enforced in 2026, further solidifying the company's market position.
- Market Impact: The pharmacopeial standard for NRCl not only enhances Niagen's brand image but may also drive consumer demand for high-quality NAD+ supplements, promoting future sales growth and market share expansion for the company.
See More
Niagen IV Launches at High-End Cruise Medi-Spa Clinics
- New Partnership: Niagen Bioscience has partnered with OneSpaWorld to offer pharmaceutical-grade Niagen IV at over 80 high-end cruise Medi-Spa clinics, marking its first entry into the cruise market, which is expected to significantly enhance brand visibility and market share.
- Market Expansion: This collaboration provides Niagen IV with a new access point outside the U.S., catering to high-end consumers seeking health and longevity experiences while on vacation, thereby driving sales growth and brand influence.
- Product Advantages: The next-generation Niagen IV formulation offers 75% shorter infusion times and a faster rise in NAD+ blood levels compared to traditional NAD+ IV, which is anticipated to improve patient experience and attract more customers.
- Strategic Implications: By partnering with OneSpaWorld, Niagen Bioscience not only expands its clinical channels but also strengthens its competitive position in the global health and longevity market, further solidifying its industry leadership.
See More
Niagen Bioscience Increases Share Repurchase Program to $20 Million
- Repurchase Program Expansion: Niagen Bioscience has increased its share repurchase program authorization from $10 million to $20 million, reflecting the company's confidence in its stock value, which is expected to enhance investor sentiment and potentially boost stock performance.
- Repurchase Progress: As of March 17, 2026, the company has repurchased approximately $2.6 million of its common stock under the program, indicating proactive measures to protect shareholder interests amid market fluctuations and reinforcing confidence in its financial health.
- Performance Beats Expectations: Niagen Bioscience reported a GAAP EPS of $0.05, beating estimates by $0.03, and revenue of $33.84 million, exceeding expectations by $2.14 million, demonstrating the company's ability to maintain strong growth in a competitive supplement market.
- Future Growth Targets: The company aims for a revenue growth of 10-15% by 2026 while expanding its injectable product line, indicating strategic decisions focused on product diversification and market share enhancement to further solidify its market position.
See More
Niagen Bioscience Expands Share Repurchase Program to $20 Million
- Program Expansion: Niagen Bioscience has increased its share repurchase program authorization from $10 million to $20 million, reflecting the company's strong confidence in its long-term strategy and value, which is expected to enhance market recognition of its stock.
- Repurchase Progress: As of March 17, 2026, the company has repurchased approximately $2.6 million of its common stock, indicating proactive measures taken to capitalize on market undervaluation, thereby strengthening investor trust.
- Flexibility in Repurchases: The repurchase program is authorized through October 31, 2027, allowing the company to execute buybacks flexibly based on market conditions, potentially through open market transactions or privately negotiated deals, enhancing capital management flexibility.
- Strategic Implications: CEO Rob Fried emphasized that the repurchase program not only reflects confidence in the company's fundamentals but also aims to leverage the disconnect in market valuation of NAGE, thereby creating long-term value for shareholders and further solidifying the company's market position.
See More
Niagen Bioscience to Participate in ROTH Conference
- Management Participation: Niagen Bioscience's senior management will attend the 2026 ROTH Conference, showcasing the company's leadership in healthy aging and likely attracting investor interest while enhancing brand visibility.
- CEO Panel Discussion: CEO Rob Fried will participate in the Technologies Advancing Healthy Aging panel on March 23, with the livestream broadening audience access to the company's innovations in NAD+ science, potentially fostering future investment opportunities.
- One-on-One Investor Meetings: Rob Fried and CFO Ozan Pamir will engage in face-to-face meetings with institutional investors, strengthening relationships with potential investors and driving company financing and market expansion.
- Industry Networking Platform: The conference will gather executives from numerous private and public companies, providing small group discussions and analyst-selected fireside chats, facilitating knowledge sharing and collaboration within the industry, thereby enhancing Niagen's influence in the sector.
See More
Niagen Bioscience Surpasses 300 Research Agreements, Strengthening NAD+ Research
- Research Agreement Milestone: Niagen Bioscience's external research program has surpassed 300 material transfer agreements (MTAs), marking its leading position in global NAD+ research support and is expected to further enhance the company's influence in the healthy aging sector.
- Clinical Research Outcomes: The program has contributed to the publication of 45 clinical studies, demonstrating the effectiveness and safety of Niagen as an NAD+ booster, thereby enhancing its credibility and competitive edge in the scientific community.
- International Collaboration Expansion: With agreements established with over 200 institutions across 34 countries, the growing global interest in NAD+ biology positions Niagen as a trusted NAD+ booster for researchers, promoting independence and rigor in scientific research.
- Future Research Directions: Niagen Bioscience plans to expand its research into areas such as topical applications and pharmaceutical-grade Niagen intravenous injections, aiming to meet the increasing interest in NAD+ biology and further explore its potential in health and aging.
See More
